Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteric Premixed Film Coating Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteric Premixed Film Coating Powder market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Acid-labile drugs degrade in gastric fluid, causing reduced efficacy or gastric irritation – but uncoated tablets lack protection. Enteric premixed film coating powder solves this with pH-sensitive polymers (dissolving at pH 5.5–7.0) that protect drugs in the stomach and enable targeted intestinal release. Key drivers include generic enteric formulations, traditional Chinese medicine modernization, and bioavailability improvement.
The global market for Enteric Premixed Film Coating Powder was estimated to be worth US$ 79 million in 2025 and is projected to reach US$ 119 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production reached approximately 2,830 tons, with an average price of US$ 26,500 per ton.
Enteric premixed film coating powder is a composite powder or pre-blended mixture specifically designed for enteric coating of tablets or granules. It is mainly composed of enteric polymers, excipients, plasticizers, and functional additives. Its primary function is to protect the drug from degradation in the stomach and enable release at specific sites in the intestine, thereby improving drug stability and targeted efficacy. The powder can be directly used in coating or spraying processes and is a commonly used excipient in enteric oral solid dosage forms.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098449/enteric-premixed-film-coating-powder
Market Segmentation & Key Players
The Enteric Premixed Film Coating Powder market is segmented as below:
Leading Suppliers: Colorcon, Kerry, Alsiano, Seppic, Imerys, Tianjing ILE, Yuekang Pharmaceutical Group, Lianyungang Wantai Pharm Excipients Tech, Lianyungang Huanyu Bitumen, Shanghai Inno-polymer Pharmaceutical Technology, Lianyungang Hengyang Pharmaceutical.
Segment by Type: Standard Enteric Type | Controlled-Release Enteric Type | Targeted Enteric Type
Segment by Application: Western Medicine | Traditional Chinese Medicine
Exclusive Industry Insights
Discrete spray-dried powder manufacturing: Enteric premix powders are manufactured via spray drying or dry blending – enteric polymers (methacrylic acid copolymers, HPMCAS, shellac) combined with plasticizers (triethyl citrate, PEG), anti-tack agents (talc, glyceryl monostearate), and pigments. Particle size optimized for aqueous film coating (D90 <50μm).
Technical differentiation – coating types:
- Standard Enteric Type (55% revenue): pH 5.5–6.0 dissolution (upper intestine). For acid-labile drugs, NSAID irritation protection. Largest segment.
- Controlled-Release Enteric Type (30% revenue): Combined enteric + sustained-release. For once-daily formulations, colonic delivery. Fastest-growing (CAGR 7.2%).
- Targeted Enteric Type (15% revenue): pH 6.5–7.0 dissolution (lower intestine/colon). For IBD drugs, peptide delivery. Highest value, specialized applications.
Recent 6-month data (Oct 2025 – Mar 2026):
- Western medicine dominates (72% revenue), including PPIs, NSAIDs, mesalamine.
- Traditional Chinese medicine fastest-growing (CAGR 7.5%), with modernization of herbal tablets.
- Aqueous enteric coating (water-based) now 85% of applications (vs. solvent-based 15%).
User case – Generic PPI manufacturer (India, 5 billion tablets/year): Using standard enteric premix powder (pH 6.0 dissolution) for omeprazole delayed-release tablets achieved bioequivalence to branded product. Coating process: 35–40°C inlet temperature, 15–20% weight gain. Batch-to-batch uniformity improved with pre-blended system.
Application insights: Western Medicine (72%) – PPIs (omeprazole, lansoprazole), NSAIDs (aspirin, ibuprofen), mesalamine (UC), pancreatic enzymes. Traditional Chinese Medicine (28%) – enteric-coated herbal tablets, protecting active compounds from gastric degradation.
Key enteric polymers:
| Polymer | pH Dissolution | Common Use |
|---|---|---|
| Methacrylic acid copolymer (Eudragit L) | 5.5–6.0 | Standard enteric |
| Methacrylic acid copolymer (Eudragit S) | 6.5–7.0 | Colonic delivery |
| HPMCAS | 5.0–5.5 | ASD + enteric |
| Shellac | 6.0–7.0 | Natural, moisture barrier |
Regional snapshot: Asia-Pacific leads with 52% revenue share (China 38%, India 12%), driven by generic and TCM manufacturing. North America holds 22%, Europe 18%.
Conclusion
The enteric premixed film coating powder market grows steadily, driven by generic enteric formulations, TCM modernization, and targeted delivery demands. Success depends on polymer selection, batch consistency, and aqueous coating compatibility. The projected US$ 119 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
